Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 19, Issue 8, Pages 1874-1882Publisher
WILEY
DOI: 10.1111/jth.15358
Keywords
anticoagulant; bariatric surgery; direct oral anticoagulant; obesity; venous thromboembolism
Categories
Ask authors/readers for more resources
The review examined the use of DOACs for VTE treatment and prevention in patients with obesity, as well as their application in bariatric surgery. Updated guidance recommendations on the use of DOACs in patients with obesity for VTE treatment and prevention were provided.
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and prevention in patients with obesity, including phase 3, phase 4, meta-analyses, and pharmacokinetic and pharmacodynamics studies. In addition, we reviewed available data regarding DOACs in bariatric surgery. We provide updated guidance recommendations on using DOACs in patients with obesity for treatment and prevention of VTE, as well as following bariatric surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available